Overexpression of receptor tyrosine kinase Axl promotes tumor cell invasion and survival in pancreatic ductal adenocarcinoma

Cancer

Volumn 117, Issue 4, 2011, Pages 734-743

  Wang, Huamin ^a   Song, Xianzhou ^a   Weng, Hua ^a   Logsdon, Craig D ^a   Rashid, Asif ^a   Fleming, Jason B ^a   Abbruzzese, James L ^a   Gomez, Henry F ^a   Evans, Douglas B ^a,b  

^a UNIVERSITY OF TEXAS   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

Akt; Axl; Gas6; invasion; pancreatic cancer; prognosis; receptor tyrosine kinase

Indexed keywords

GROWTH ARREST SPECIFIC PROTEIN 6; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN KINASE AXL; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG; TYROSINE KINASE RECEPTOR; TYROSINE KINASE RECEPTOR AXL;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CELL INVASION; CELL SURVIVAL; CONTROLLED STUDY; DISTANT METASTASIS; FEMALE; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR CELL; CANCER PROGNOSIS; CARCINOGENESIS; DISEASE ASSOCIATION; ENZYME ACTIVATION; ENZYME ACTIVITY; IN VITRO STUDY; RECURRENCE FREE SURVIVAL; TUMOR INVASION; TUMOR VOLUME;

ADENOCARCINOMA; AGED; CARCINOMA, PANCREATIC DUCTAL; CELL LINE, TUMOR; FEMALE; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; PANCREATIC NEOPLASMS; PROGNOSIS; PROTO-ONCOGENE PROTEINS; RECEPTOR PROTEIN-TYROSINE KINASES; RNA, SMALL INTERFERING; UP-REGULATION;

EID: 79551709511     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25483     Document Type: Article

References (32)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin. 2006; 56: 106-130.
2. Hezel AF, Kimmelman AC, Stanger BZ, Bardeesy N, Depinho RA., Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev. 2006; 20: 1218-1249.
3. Ruggeri BA, Huang L, Berger D, et al. Molecular pathology of primary and metastatic ductal pancreatic lesions: analyses of mutations and expression of the p53, mdm-2, and p21/WAF-1 genes in sporadic and familial lesions. Cancer. 1997; 79: 700-716.
4. Schlessinger J., Cell signaling by receptor tyrosine kinases. Cell. 2000; 103: 211-225.
5. Gschwind A, Fischer OM, Ullrich A., The discovery of receptor tyrosine kinases: targets for cancer therapy. Nat Rev Cancer. 2004; 4: 361-370. (Pubitemid 38579482)
6. Hafizi S, Dahlback B., Gas6 and protein S. Vitamin K-dependent ligands for the Axl receptor tyrosine kinase subfamily. FEBS J. 2006; 273: 5231-5244.
7. Sasaki T, Knyazev PG, Clout NJ, et al. Structural basis for Gas6-Axl signalling. EMBO J. 2006; 25: 80-87.
8. Fridell YW, Jin Y, Quilliam LA, et al. Differential activation of the Ras/extracellular-signal-regulated protein kinase pathway is responsible for the biological consequences induced by the Axl receptor tyrosine kinase. Mol Cell Biol. 1996; 16: 135-145.
9. Hutterer M, Knyazev P, Abate A, et al. Axl and growth arrest-specific gene 6 are frequently overexpressed in human gliomas and predict poor prognosis in patients with glioblastoma multiforme. Clin Cancer Res. 2008; 14: 130-138.
10. O'Bryan JP, Frye RA, Cogswell PC, et al. axl, a transforming gene isolated from primary human myeloid leukemia cells, encodes a novel receptor tyrosine kinase. Mol Cell Biol. 1991; 11: 5016-5031.
11. Vajkoczy P, Knyazev P, Kunkel A, et al. Dominant-negative inhibition of the Axl receptor tyrosine kinase suppresses brain tumor cell growth and invasion and prolongs survival. Proc Natl Acad Sci U S A. 2006; 103: 5799-5804.
12. Chung BI, Malkowicz SB, Nguyen TB, Libertino JA, McGarvey TW., Expression of the proto-oncogene Axl in renal cell carcinoma. DNA Cell Biol. 2003; 22: 533-540.
13. Craven RJ, Xu LH, Weiner TM, et al. Receptor tyrosine kinases expressed in metastatic colon cancer. Int J Cancer. 1995; 60: 791-797.
14. Meric F, Lee WP, Sahin A, Zhang H, Kung HJ, Hung MC., Expression profile of tyrosine kinases in breast cancer. Clin Cancer Res. 2002; 8: 361-367.
15. Nakano T, Tani M, Ishibashi Y, et al. Biological properties and gene expression associated with metastatic potential of human osteosarcoma. Clin Exp Metastasis. 2003; 20: 665-674.
16. Nemoto T, Ohashi K, Akashi T, Johnson JD, Hirokawa K., Overexpression of protein tyrosine kinases in human esophageal cancer. Pathobiology. 1997; 65: 195-203.
17. Shieh YS, Lai CY, Kao YR, et al. Expression of axl in lung adenocarcinoma and correlation with tumor progression. Neoplasia. 2005; 7: 1058-1064.
18. van, Ginkel PR, Gee RL, Shearer RL, et al. Expression of the receptor tyrosine kinase Axl promotes ocular melanoma cell survival. Cancer Res. 2004; 64: 128-134.
19. Wu CW, Li AF, Chi CW, et al. Clinical significance of AXL kinase family in gastric cancer. Anticancer Res. 2002; 22: 1071-1078.
20. Zhang YX, Knyazev PG, Cheburkin YV, et al. AXL is a potential target for therapeutic intervention in breast cancer progression. Cancer Res. 2008; 68: 1905-1915.
21. Jacob AN, Kalapurakal J, Davidson WR, et al. A receptor tyrosine kinase, UFO/Axl, and other genes isolated by a modified differential display PCR are overexpressed in metastatic prostatic carcinoma cell line DU145. Cancer Detect Prev. 1999; 23: 325-332.
22. Holland SJ, Powell MJ, Franci C, et al. Multiple roles for the receptor tyrosine kinase axl in tumor formation. Cancer Res. 2005; 65: 9294-9303.
23. Wang H, Wang H, Zhang W, Fuller GN., Tissue microarrays: applications in neuropathology research, diagnosis, and education. Brain Pathol. 2002; 12: 95-107.
24. Wang H, Wang H, Shen W, et al. Insulin-like growth factor binding protein 2 enhances glioblastoma invasion by activating invasion-enhancing genes. Cancer Res. 2003; 63: 4315-4321. (Pubitemid 36950996)
25. Gustafsson A, Martuszewska D, Johansson M, et al. Differential expression of Axl and Gas6 in renal cell carcinoma reflecting tumor advancement and survival. Clin Cancer Res. 2009; 15: 4742-4749.
26. Koorstra JB, Karikari CA, Feldmann G, et al. The Axl receptor tyrosine kinase confers an adverse prognostic influence in pancreatic cancer and represents a new therapeutic target. Cancer Biol Ther. 2009; 8: 618-626.
27. Li Y, Ye X, Tan C, et al. Axl as a potential therapeutic target in cancer: role of Axl in tumor growth, metastasis and angiogenesis. Oncogene 2009; 28: 3442-3455.
28. Liu L, Greger J, Shi H, et al. Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of AXL. Cancer Res. 2009; 69: 6871-6878.
29. Gjerdrum C, Tiron C, Hoiby T, et al. Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival. Proc Natl Acad Sci U S A. 2010; 107: 1124-1129.
30. Lee WP, Liao Y, Robinson D, Kung HJ, Liu ET, Hung MC., Axl-gas6 interaction counteracts E1A-mediated cell growth suppression and proapoptotic activity. Mol Cell Biol. 1999; 19: 8075-8082.
31. Tai KY, Shieh YS, Lee CS, Shiah SG, Wu CW., Axl promotes cell invasion by inducing MMP-9 activity through activation of NF-kappaB and Brg-1. Oncogene. 2008; 27: 4044-4055.
32. Messersmith WA, Rajeshkumar NV, Tan AC, et al. Efficacy and pharmacodynamic effects of bosutinib (SKI-606), a Src/Abl inhibitor, in freshly generated human pancreas cancer xenografts. Mol Cancer Ther. 2009; 8: 1484-1493.